OR WAIT null SECS
September 03, 2025
Article
A recap 8 clinical trials in cardiovascular care to know from the European Society of Cardiology Congress 2025.
Patients with hypercholesterolemia on individualized maximally tolerated dose of statins achieved guideline-recommended LDL-C levels on inclisiran.
September 02, 2025
Merck’s investigational oral PCSK9 inhibitor reduced LDL-C, non-HDL-C, ApoB, and LP(a) significantly compared to placebo after 24 weeks.
Ionis Therapeutics, Inc. also announced plans to submit an sNDA for olezarsen based on these trial results by the end of 2025.
August 31, 2025
Olezarsen shows promise in significantly lowering triglyceride levels in patients with hypertriglyceridemia.
August 21, 2025
According to investigators, individuals with 3 or more risk factors for metabolic syndrome have a 40% greater risk of developing Parkinson’s.
August 20, 2025
A series of phase 2/3 trials collectively indicate the overall lipid-lowering effects of obicetrapib in a 5 mg dose, a 10 mg dose, and 10 mg with ezetimibe.
August 13, 2025
Parent company Response Pharmaceuticals has announced RDX-002’s achievement of its primary endpoint, with more data to come from an ongoing extension.
August 06, 2025
July delivered 9 impactful advancements across the gamut of disciplines in cardiology.
August 04, 2025
Discover the evolving landscape of hypertriglyceridemia treatment, focusing on innovative therapies and improved diagnostic strategies for FCS and MCS.
